Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      GHIT Fund Announces New Investments: A Total of 750 Million Yen in Drugs for Malaria and Chagas Disease, Vaccine for Malaria, and Diagnostics for Tuberculosis


      News provided by

      GHIT Fund

      Nov 04, 2021, 00:09 ET

      Share this article

      Share this article


      TOKYO, Nov. 4, 2021 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total of approximately 750 million yen (US$6.6 million*) to invest in six partnerships to develop new lifesaving drugs for malaria and Chagas Disease, a vaccine for malaria, and diagnostics for tuberculosis (TB).** (Appendix 1 & 2)

      Continue Reading
      Portfolio analysis of active and completed projects. Note: all amounts are listed at the exchange rate of USD1 = JPY¥113.68, the approximate exchange rate on October 29, 2021.
      Portfolio analysis of active and completed projects. Note: all amounts are listed at the exchange rate of USD1 = JPY¥113.68, the approximate exchange rate on October 29, 2021.

      "We are pleased to announce our new investments in diagnostics for tuberculosis, a vaccine and drug for malaria, and drug discovery for Chagas diseases," said GHIT's acting CEO Kio Yamabe. "Even in the midst of a pandemic, we are committed to advancing product development for patients suffering from neglected diseases by strengthening partnerships with R&D and funding partners."

      A Diagnostic for Tuberculosis
      GHIT will invest 83.4 million yen (US$733K) in evaluating the performance of the Lung Flute/Lung Flute ECO to improve sputum-based TB diagnosis primarily in vulnerable groups in a TB-endemic setting. The Lung Flute, invented in the early 2000s, is a positive expiratory pressure (PEP) device that creates sound waves that, when blown, loosens phlegm in the lungs and enables individuals to increase the quantity and quality of sputum they can produce. The Lung Flute ECO is a more recently developed paper-based version of the Lung Flute that is inexpensive enough to be used as a disposable, point-of-care tool to aid in sputum production in low-resource settings.

      A Vaccine and Drug for Malaria
      GHIT will also invest 469 million yen (US$4.1M) in clinical development of two Placental Malaria (PM) vaccine candidates known as PAMVAC and PRIMVAC. PM constitutes a major health problem, causing an estimated 10,000 maternal and 200,000 infant deaths annually. Animal immunization and clinical trial data and results show lasting immune responses and have demonstrated that both adjuvanted vaccine candidates are safe and well-tolerated. However, further optimization of the current candidates is essential to address emerging different variants. GHIT will make another investment of 83.8 million yen (US$737K) in malaria drug development for a new drug design approach known as PROteolysis-TArgeting Chimeras or PROTACs. PROTACs acts not as an inhibitor of target functions, but as a protein degrader hijacking the proteasome to destroy target proteins.

      Chagas Drug Discovery
      GHIT will also invest 98.9 million yen (US$870K) in further development of novel anti-Trypanosoma cruzi (T. cruzi) drugs acting against the selected target identified in a previous GHIT-invested study: the T. cruzi autophagy-regulating factor that is essential to the T. cruzi life cycle.

      Finally, GHIT will invest 19.8 million yen (US$170K) for drug screening programs. In collaboration with the Drugs for Neglected Diseases initiative (DNDi), Daiichi Sankyo Company, Limited and Takeda Pharmaceutical Company Limited will conduct a screening for hit identification for Chagas disease by utilizing their compound libraries.

      As of November 4, there are 63 ongoing projects, including 29 discovery, 24 preclinical and 10 clinical trials, in the GHIT portfolio (Appendix 3). The total amount of investments since 2013 is 26.9 billion yen (US$236 million).

      * USD1 = JPY¥113.68, the approximate exchange rate on October 29, 2021.

      ** These awarded projects were selected from a number of proposals to the RFP2021-001 for Target Research Platform, Screening Platform, Hit-to-Lead Platform, and Product Development Platform, which was open for applications from November 2020 to July 2021. The GHIT board conducted in July 2021 approved these new investments.

      The GHIT Fund is a Japan-based international public-private partnership fund (PPP) between the Government of Japan, multiple pharmaceutical companies, the Bill & Melinda Gates Foundation, the Wellcome, and the United Nations Development Programme (UNDP). The GHIT Fund invests and manages an R&D portfolio of development partnerships aimed at neglected diseases, such as malaria, tuberculosis and neglected tropical diseases that afflict the world's vulnerable and underserved populations. The GHIT Fund mobilizes the Japanese industry, academia, and research institutes to create new drugs, vaccines, and diagnostics for malaria, tuberculosis, and neglected tropical diseases, in collaboration with global partners.

      Appendix.1 New Investments

      ID/Status

      Project Title

      Collaboration Partners

      Disease/Intervention

      Stage

      Awarded Amount

      G2021-114

      New project

      Viability & Value of the Lung Flute ECO for Sputum Sample Collection and Tuberculosis Testing in Vulnerable Groups (3V Trial)

      Research Institute of Tuberculosis, Acoustic Innovation (AI), Institute for Tropical Medicine (ITM), Center for Health Promotion and Research (CHPR) also known as the TB Reference Laboratory Bamenda (TRLB)

      Tuberculosis

      Diagnostics

      Product Development

      ¥83,373,809

      (US$733,408)

      G2020-214

      New project

      Clinical development of placental malaria vaccine candidates

      Ehime University (Ehime), European Vaccine Initiative (EVI), University of Copenhagen (UCPH), Institut national de la santé et de la recherche médicale (Inserm), Institut de recherche pour le développement, Groupe de Recherche Action en Santé (GRAS), Noguchi Memorial Institute for Medical Research

      Malaria

      Vaccine

      Pre-Clinical Development

      ¥469,292,404

      (US$4,128,188)

      S2021-121

      New project

      Screening project between Takeda Pharmaceutical Company Ltd. and DNDi

      Takeda Pharmaceutical Company Ltd., Drugs for Neglected Diseases initiative (DNDi)

      Chagas Disease

      Drug

      Hit Identification

      ¥8,994,695

      (US$79,123)

      S2021-122

      New project

      Screening project between Daiichi Sankyo Company Limited and DNDi

      Daiichi Sankyo Company Limited, Drugs for Neglected Diseases initiative (DNDi)

      Chagas Disease

      Drug

      Hit Identification

      ¥10,976,301

      (US$96,554)

      T2021-152

      New project

      Identification and Validation of potential Plasmodium E3 Ligases for PROTAC Platform

      FIMECS, Inc., National Center for Genetic Engineering and Biotechnology (BIOTEC)

      Malaria

      Drug

      Target Identification

      ¥83,858,773

      (US$737,674)

      T2021-153

      Continued

      project

      Autophagy as a novel drug-development target for Chagas disease

      National Institute of Advanced Industrial Science and Technology (AIST), Drugs for Neglected Diseases initiative (DNDi)

      Chagas Disease

      Drug

      Target Identification

      ¥98,920,080

      (US$870,163)


      *All amounts are listed at the exchange rate of USD1 = JPY¥113.68, the approximate exchange rate on October 29, 2021.

      Appendix.2 Project Details

      G2021-114

      Project Title

      Viability & Value of the Lung Flute ECO for Sputum Sample Collection and Tuberculosis Testing in Vulnerable Groups (3V Trial)

      Collaboration
      Partners

      Research Institute of Tuberculosis, Acoustic Innovation (AI), Institute for Tropical Medicine (ITM), Center for Health Promotion and Research (CHPR) also known as the TB Reference Laboratory Bamenda (TRLB)

      Disease

      Tuberculosis

      Intervention

      Diagnostics

      Stage

      Product Development

      Awarded Amount

      ¥83,373,809 (US$733,408)

      Status

      New project

      Summary

      [Project objective]

      The primary objective is to evaluate the proportion of presumptive TB clients who test positive for TB after using the Lung Flute ECO or the Lung Flute® HR, as compared to the standard of care with no device to aid in sputum production.

       

      The secondary objectives are:

      1. To compare the proportion of presumptive TB clients who are able to submit sputum samples for testing after using Lung Flute ECO prototype, Lung Flute® HR and the standard of care

      2. To compare average quality and quantity of sputum samples submitted using Lung Flute ECO prototype, Lung Flute®, and the standard of care

      3. To assess the feasibility, safety, user satisfaction, and cost effectiveness of the Lung Flute ECO prototype and the Lung Flute® HR as compared to the standard of care

       

      [Project design]

      We will evaluate performance of the Lung Flute ECO and the Lung Flute® HR across multiple sites in Cameroon. The study focuses on evaluating test access and accuracy in patient groups with documented challenges to produce sputum on demand, including children 6-14 years of age, women, the elderly, people living with HIV, people admitted to hospital, and asymptomatic persons screening positive for TB by digital chest x-ray.

      Project Detail

      https://www.ghitfund.org/investment/portfoliodetail/detail/194/en

      G2020-214

      Project Title

      Clinical development of placental malaria vaccine candidates

      Collaboration
      Partners

      Ehime University (Ehime), European Vaccine Initiative (EVI), University of Copenhagen (UCPH), Institut national de la santé et de la recherche médicale (Inserm), Institut de recherche pour le développement, Groupe de Recherche Action en Santé (GRAS), Noguchi Memorial Institute for Medical Research

      Disease

      Malaria

      Intervention

      Vaccine

      Stage

      Pre-Clinical Development

      Awarded Amount

      ¥469,292,404 (US$4,128,188)

      Status

      New project

      Summary

      [Project objective]

      This project will advance and accelerate the development of a PM vaccine by establishing a global portfolio of vaccine candidates that will be evaluated according to the following objectives:

       

      1. Objective 1: to assess the longevity of the immune response induced by PRIMVAC through an extended follow up of PRIMVAC vaccinated women in Burkina Faso

      2. Objective 2: to assess the capacity of adjuvanted PRIMVAC to boost naturally acquired VAR2CSA specific immune responses

      3. Objective 3: to assess the potential of a capsid-like particle (CLP) based vaccine formulation to increase vaccine induced immune responses

      4. Objective 4: to evaluate cross-reactivity of the immune responses induced by VAR2CSA antigens

       

      Generated data will inform the next steps of PM vaccine development, will allow a decision on the formulation for further development and the preparation of a larger phase II immunogenicity study.

       

      [Project design]

      Recombinant soluble proteins are often thought to induce an immune response of insufficient strength and breadth to confer full protection. However, we have observed that our vaccine candidates, especially PRIMVAC, produced a lasting immune response. We propose therefore to further characterize the longevity of the PRIMVAC-induced immune response in women in malaria-endemic areas, as well as the capacity of the vaccine to boost and broaden a natural acquired immune response.

      We will also undertake an in-depth analysis of the cross-reactivity against the different haplotypes by the immune response elicited by the PM vaccine candidates.

      Additionally, we propose to undertake the pre-clinical development of PAMVAC-CLP. PAMVAC-CLP is an improved version of PAMVAC, where a capsid-like particle (CLP) has been added as backbone, thereby potentially improving immunogenicity, cross-reactivity and longevity of the induced immune response. Taken together, PRIMVAC and PAMVAC-CLP, together with additional PRIMVAC variants in early pre-clinical evaluation constitute a promising portfolio of PM vaccine candidates.

      Project Detail

      https://www.ghitfund.org/investment/portfoliodetail/detail/195/en

      S2021-121

      Project Title

      Screening project between Takeda Pharmaceutical Company Ltd. and DNDi

      Collaboration
      Partners

      Takeda Pharmaceutical Company Ltd., Drugs for Neglected Diseases initiative (DNDi)

      Disease

      Chagas Disease

      Intervention

      Drug

      Stage

      Hit Identification

      Awarded Amount

      ¥8,994,695 (US$79,123)

      Status

      New project

      Summary

      This is a screening project between Takeda Pharmaceutical Company Ltd. and DNDi.

      Project Detail

      https://www.ghitfund.org/investment/portfoliodetail/detail/198/en

      S2021-122

      Project Title

      Screening project between Daiichi Sankyo Company Limited and DNDi

      Collaboration
      Partners

      Daiichi Sankyo Company Limited, Drugs for Neglected Diseases initiative (DNDi)

      Disease

      Chagas Disease

      Intervention

      Drug

      Stage

      Target Identification

      Awarded Amount

      ¥10,976,301 (US$96,554)

      Status

      New project

      Summary

      This is a screening project between Daiichi Sankyo Company Limited and DNDi.

      Project Detail

      https://www.ghitfund.org/investment/portfoliodetail/detail/199/en

      T2021-152

      Project Title

      Identification and Validation of potential Plasmodium E3 Ligases for PROTAC Platform

      Collaboration
      Partners

      FIMECS, Inc., National Center for Genetic Engineering and Biotechnology (BIOTEC)

      Disease

      Malaria

      Intervention

      Drug

      Stage

      Target Identification

      Awarded Amount

      ¥83,858,773 (US$737,674)

      Status

      New project

      Summary

      [Project objective]

      To identify a chemical warhead(s) that can recruit a parasite ubiquitin E3 ligase(s) to degrade a target parasite protein, which will constitute a platform for the design of protein degrader antimalarials.

       

      [Project design]

      We will design and synthesize a library of protein degraders for degradation experiments. The test compounds will be designed with various chemical warheads against a variety of ubiquitin E3 ligases joined to a warhead specific to the Plasmodium parasite bifunctional dihydrofolate reductase-thymidylate synthase, a well-studied parasite protein. The protein degrader that trigger target protein degradation will be used for designing follow-on compounds, including probe compounds for biochemical characterization of Plasmodium ubiquitin E3 ligase(s) that interact with the ubiquitin E3 ligase warhead and those protein degraders for optimizing the degradation of target.

      Project Detail

      https://www.ghitfund.org/investment/portfoliodetail/detail/196/en

      T2021-153

      Project Title

      Autophagy as a novel drug-development target for Chagas disease

      Collaboration
      Partners

      National Institute of Advanced Industrial Science and Technology (AIST), Drugs for Neglected Diseases initiative (DNDi)

      Disease

      Chagas Disease

      Intervention

      Drug

      Stage

      Target Identification

      Awarded Amount

      ¥98,920,080 (US$870,163)

      Status

      Continued project

      Summary

      [Project objective]

      The overall goal of this project is to obtain initial hit compounds amenable for further development as novel anti-T. cruzi drugs acting through inhibition of the parasite autophagy-regulating factor.

       

      [Project design]

      To achieve the goals of the project, we use two different but complementary screening approaches, a Fragment-Based Drug Discovery (FBDD) approach and a "classical" screening of an anti-T. cruzi compound library (the DNDi library) against the autophagy-regulating factor target. For the FBDD approach, we employ the DNA-encoded library (DEL) technology, where two fragments are intended to bind simultaneously to the protein in the same vicinity. On the other hand, the DNDi library consists of compounds already confirmed to have promising intracellular anti-T. cruzi activity in whole cell-based assays. In this project, we will require that both the identified hits and the target protein be druggable. We consider that the ideal initial hit compound should not only bind to the drug target and inhibit enzyme activity, but also have a protein-compound binding state that will facilitate subsequent modification during Hit-To-Lead and Lead Optimization steps. Since this requires a structural understanding of the compound-protein interactions, determination of the three-dimensional structures of the hit compound-target molecule complexes will be a critical part of this project, as well. Notably, hit compounds obtained from the FBDD approach will be initially selected based only on their target-binding and enzyme inhibition activity independently of their pharmacological activities. The identified compounds must have the potential to evolve and be optimized during the subsequent development stages to acquire the required properties.

      Project Detail

      https://www.ghitfund.org/investment/portfoliodetail/detail/197/en


      *All amounts are listed at the exchange rate of USD1 = JPY¥113.68, the approximate exchange rate on October 29, 2021.

      Appendix.3 Investment Overview (As of November 4, 2021)

       1. Investment to date

      Total investments 26.9 billion yen (US$236 million*)
      Total invested projects 111(active projects 63, completed projects 48)

      Portfolio analysis (active projects + completed projects) 

      To know more about GHIT investments, please visit
      Investment Overview: https://www.ghitfund.org/investment/overview/en
      Portfolio: https://www.ghitfund.org/investment/portfolio/en
      Advancing Portfolio: https://www.ghitfund.org/investment/advancingportfolio/en
      Clinical Candidates: https://www.ghitfund.org/investment/clinicalcandidates/en

      ­For more information, contact:
      Katy Lenard at +1-301-280-5719 or [email protected]
      Bumpei Tamamura at +81-36441-2032 or [email protected]

      SOURCE GHIT Fund

      Modal title

      Also from this source

      Total Investment of Approx. USD 6.8 Million in Product Development for Malaria, NTDs and Other Emerging & Re-emerging Infectious Diseases Such as Ebola Disease

      The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1.06 billion (USD 6.8 million1) in nine...

      GHIT Fund Launches "NTDpedia" to Help Turn Apathy Into Action Against Neglected Tropical Diseases

      The Global Health Innovative Technology (GHIT) Fund announced the launch of "NTDpedia: Your Guide to Neglected Tropical Diseases." Designed as an...

      More Releases From This Source

      Explore

      Banking & Financial Services

      Banking & Financial Services

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.